148 related articles for article (PubMed ID: 24324108)
21. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
23. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
[TBL] [Abstract][Full Text] [Related]
24. Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not.
Grant R; Walker M; Hadley D; Barton T; Osborn C
J Neurooncol; 2002 May; 57(3):241-5. PubMed ID: 12125987
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy.
Santos JG; Faria G; Cruz WDCSD; Fontes CA; Schönthal AH; Quirico-Santos T; da Fonseca CO
Surg Neurol Int; 2020; 11():389. PubMed ID: 33282452
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
28. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
29. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
Stearns V; Coop A; Singh B; Gallagher A; Yamauchi H; Lieberman R; Pennanen M; Trock B; Hayes DF; Ellis MJ
Clin Cancer Res; 2004 Nov; 10(22):7583-91. PubMed ID: 15569989
[TBL] [Abstract][Full Text] [Related]
30. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
[TBL] [Abstract][Full Text] [Related]
32. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
[TBL] [Abstract][Full Text] [Related]
34. Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.
de Saldanha da Gama Fischer J; Costa Carvalho P; da Fonseca CO; Liao L; Degrave WM; da Gloria da Costa Carvalho M; Yates JR; Domont GB
J Proteome Res; 2011 Jan; 10(1):153-60. PubMed ID: 20806975
[TBL] [Abstract][Full Text] [Related]
35. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Afra D; Sipos L; Vitanovics D
Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942
[TBL] [Abstract][Full Text] [Related]
36. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
37. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
[TBL] [Abstract][Full Text] [Related]
38. Intranasal administration of perillyl alcohol activates peripheral and bronchus-associated immune system in vivo.
D'Alincourt Salazar M; da Silva RF; Da Fonseca CO; Lagrota-Candido J; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2014 Feb; 62(1):59-66. PubMed ID: 24257817
[TBL] [Abstract][Full Text] [Related]
39. Influence of GSTM1 and GSTT1 polymorphisms on the survival rate of patients with malignant glioma under perillyl alcohol-based therapy.
Silva MM; Da Fonseca CO; Moura-Neto R; Carvalho JF; Quirico-Santos T; Carvalho MG
Genet Mol Res; 2013 May; 12(2):1621-30. PubMed ID: 23765968
[TBL] [Abstract][Full Text] [Related]
40. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]